Oral propranolol is successful in treating periocular infantile haemangiomas.

Article

A study published in the Archives of Ophthalmology has confirmed the safety and efficacy of oral propranolol for the treatment of periocular infantile haemangiomas.

A study published in the Archives of Ophthalmology has confirmed the safety and efficacy of oral propranolol for the treatment of periocular infantile haemangiomas.

Dr Tara G. Missoi et al., Department of Ophthalmology, University of Missouri–Columbia, Missouri, USA, treated periocular hemangiomas from 17 children with oral propranolol 3 times a day. To document haemangioma, size serial examinations and external photography were used. The starting dose was 0.5mg for 1 week, then 1mg for 1 week and 2mg for the remainder of treatment.

Findings demonstrated that propranolol reduced the size of all infantile haemangiomas. Astigmatism was lowered by 33%, surface area reduced by 39% and vision was equalized in all but 1 child. The mean change in surface area was 61% of the original size. In 2 patients there was some rebound growth that did not require retreatment. Amblyopia was found in 7 patients and 1 patient experienced a benign episode of bradycardia.

Early use of propranolol is effective in treating and improving visual acuity in periocular infantile hemangiomas.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.